Issues in stinging insect allergy immunotherapy: A review

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 4, 2008, Pages 343-347

  Finegold, Ira ^a,b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b School of Medicine ^*  (United States)

Author keywords

Hymenoptera venom immunotherapy; Immunotherapy; Omalizumab and immunotherapy; Rush immunotherapy

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BEE VENOM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DESLORATADINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FEXOFENADINE; HYMENOPTERA VENOM; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G4; INSECT VENOM; MONTELUKAST; OMALIZUMAB; PLACEBO; PREDNISONE; RANITIDINE; STEROID; TERFENADINE; VENOM; ARTHROPOD VENOM; INSECT PROTEIN; MONOCLONAL ANTIBODY;

ALLERGIC REACTION; ANAPHYLAXIS; CONTROLLED STUDY; DESENSITIZATION; DISEASE SEVERITY; DRUG WITHDRAWAL; HUMAN; HYMENOPTERA; IMMUNOTHERAPY; INSECT ALLERGY; INSECT STING; PARAMETER; PREMEDICATION; PRIORITY JOURNAL; PUBLICATION; REVIEW; SKIN TEST; SYSTEMIC MASTOCYTOSIS; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG CONTRAINDICATION; DRUG POTENTIATION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGY; INSECT BITE; STANDARD; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT WITHDRAWAL;

ALLERGENS; ANIMALS; ANTIBODIES, MONOCLONAL; ARTHROPOD VENOMS; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; HYMENOPTERA; HYPERSENSITIVITY, IMMEDIATE; INJECTIONS, SUBCUTANEOUS; INSECT BITES AND STINGS; INSECT PROTEINS; MASTOCYTOSIS, SYSTEMIC; WITHHOLDING TREATMENT;

EID: 66149086201     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328306a007     Document Type: Review

References (25)

1. Allergen immunotherapy: a practice parameter second update 2007; J Allergy Clin Immunol;120:S25-S85.
2. Golden DB. Insect sting allergy and venom immunotherapy. Ann Allergy Asthma Immunol 2006; 96 (Suppl 1):S16-S21.
3. Muller UR. Bee venom allergy in beekeepers and their family members. Curr Opin Allergy Clin Immunol 2005; 5:343-347.
4. Brockow K, Jofer C, Behrendr H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226-232.
5. de Olano DG, Alvarez-Twose I, Esteban-Lopez M, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera anaphylaxis. J Allergy Clin Immunol 2008; 121:519-526.
6. BonnadonnaP, Zanotti R, Caruso B, et al. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol 2008; 121:256-257.
7. Cassale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117:134-140.
8. Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007; 62:963-964.
9. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008; 63:376-378.
10. Venomil. Instructions and dosage schedule for allergenic extracts Hymenoptera venom products. Spokane, WA: HollisterStier. [Accessed 16 February 2008].
11. Glerant JC, Martinez P, Guillaume C, Jounieaux V. Comparison of 2 maintenance doses (100 microg vs 200 microg) in Hymenoptera venom immunotherapy: influence of the maintenance dose on the immunologic response. Ann Allergy Asthma Immunol 2005; 94:451 -456.
12. BiloB, Bonifazi F. Advances in Hymenoptera venom immunotherapy. Curr Opin Allergy Clin Immunol 2007; 7:567-573.
13. Pharmalgen. Prescribing information. Allergenic extracts. Hymenoptera venom/ venom protein. Horsholm, Denmark: AlkAbbello, Korrektur 3 (3-01-2007).
14. Schiavino D, Nucera E, Pollastrini E, et al. Specific ultrarush desensitization in Hymenoptera venom allergic patients. Ann Allergy Asthma Immunol 2004; 92: 409-413.
15. Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol 2006; 16:79-85.
16. Pasaoglu G, Sin BA, Misirligil Z. Rush Hymenoptera venom immunotherapy is efficacious and safe. J Investig Allergol Clin Immunol 2006; 16:232-238.
17. Steiss JO, Jodicke B, Lindemann H. A modified ultrarush insect venom immunotherapy protocol for children. Allergy Asthma Proc 2006; 27:148- 150.
18. Oren E, Chegini S, Hamilos D. Ultrarush venom desensitization after systemic reactions during conventional immunotherapy. Ann Allergy Asthma Immunol 2006; 97:606-610.
19. Baenkler HW, Meusser-Storm S, Eger G. Continuous immunotherapy for Hymenoptera venom allergy using six month intervals. Allergol Immunopathol (Madr) 2005; 33:7-14.
20. Goldberg A, Confino-Cohen R. Effectiveness of maintenance bee venom immunotherapy administeredat6-month intervals. Ann Allergy Asthma Immunol 2007; 99:352-357.
21. Hafner T, DuBuske L, Kosnik M. Long-term efficacy of venom immunotherapy. Ann Allergy 2008; 100:162-165.
22. Mueller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001; 107: 81-86.
23. WohrlS,GamperS,HemmerW,et al. Premedicationwithmontelukastreduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol 2007; 144: 137-142.
24. Muller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005; 115:606-610.
25. Stumpf JL, Shehab N, Patel AC. Safety of angiotensin-converting enzyme inhibitors in patients with insect venom allergies. Ann Pharmacother 2006; 40:699-703.